Robert B. Bazemore - 06 Mar 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
06 Mar 2025
Net transactions value
+$149,997
Form type
4
Filing time
10 Mar 2025, 17:00:05 UTC
Previous filing
18 Sep 2024
Next filing
24 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $49,999 +44,642 $1.12 44,642 06 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Series A Warrants (Right to Buy) Award $49,999 +44,642 $1.12 44,642 06 Mar 2025 American Depositary Shares representing Ordinary Shares 44,642 $0.8700 Direct F1, F2
transaction AKTX Series B Warrants (Right to Buy) Award $49,999 +44,642 $1.12 44,642 06 Mar 2025 American Depositary Shares representing Ordinary Shares 44,642 $0.8700 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

Remarks:

Exhibit 24 - Power of Attorney